	US 11,673,950 B2
	ILT7 binding molecules and methods of using the same
Katherine Ann Vousden, Cambridge (GB); Julie Ann Douthwaite, Cambridge (GB); Melissa Marie Damschroder, Gaithersburg, MD (US); and Miguel Angel Sanjuan, Gaithersburg, MD (US)
Assigned to Viela Bio, Inc., Deerfield, IL (US)
Filed by Viela Bio, Inc., Gaithersburg, MD (US)
Filed on Jun. 17, 2021, as Appl. No. 17/350,271.
Application 17/350,271 is a continuation of application No. 16/083,825, granted, now 11,072,652, previously published as PCT/US2017/021616, filed on Mar. 9, 2017.
Claims priority of provisional application 62/306,125, filed on Mar. 10, 2016.
Prior Publication US 2022/0144940 A1, May 12, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61P 37/00 (2006.01); G01N 33/564 (2006.01); A61K 39/00 (2006.01); C07K 16/26 (2006.01)

CPC C07K 16/26 (2013.01) [A61P 37/00 (2018.01); G01N 33/564 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/41 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01)]

22 Claims

1. A method of treating a disease associated with ILT7-expressing cells that comprises inflammation, the method comprising administering an effective amount of an anti-Immunoglobulin-like transcript-7 (ILT7) antibody to a subject in need thereof, wherein the ILT7 antibody comprises Complementarity-Determining Regions (CDRs) HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 203, 204, 205, 208, 209, and 210, respectively, and wherein the administering is effective in treating the disease as determined by detecting a reduced level of interferon-alpha or plasmacytoid dendritic cells (pDCs) in the subject in need thereof after the administering.